health-issue
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
https://ift.tt/bm12vBk Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old from …
Read more
health-issue
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
https://ift.tt/JUzW2YL Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progress…
Read more
health-issue
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
https://ift.tt/4FVPzMi Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers fro…
Read more
health-issue
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
https://ift.tt/SV7srXF from Sanofi - Aventis Groupe https://ift.tt/Sbfp6LR via IFTTT
Read more
health-issue
Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies
https://ift.tt/BcI7X3j ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies from Sanofi - A…
Read more
health-issue
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
https://ift.tt/Ij3XSgP from Sanofi - Aventis Groupe https://ift.tt/rdPcjkR via IFTTT
Read more
health-issue
Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases
https://ift.tt/xsjCpMB ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases from Sanofi -…
Read more
health-issue
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
https://ift.tt/EcAG0nQ Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed mu…
Read more
health-issue
Press Release: Online availability of Sanofi’s half-year financial report for 2024
https://ift.tt/xwIQYg6 Online availability of Sanofi’s half-year financial report for 2024 from Sanofi - Aventis Groupe https://ift.tt/ydsvDL4 vi…
Read more
health-issue
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
https://ift.tt/FDUSs3t Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded from Sanofi - Aventis Groupe https://ift.tt/cVF…
Read more
health-issue
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
https://ift.tt/zPEl2I3 from Sanofi - Aventis Groupe https://ift.tt/qvjxlhr via IFTTT
Read more
health-issue
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
https://ift.tt/PzQ59md Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD from Sanofi - Aventis Groupe https://…
Read more
health-issue
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
https://ift.tt/PzQ59md Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD from Sanofi - Aventis Groupe https://…
Read more
health-issue
Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS
https://ift.tt/5CyKS1v Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS from Sanofi - Aventis Gr…
Read more
health-issue
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
https://ift.tt/0rdakEh Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM from Sano…
Read more
health-issue
Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy
https://ift.tt/GJmyQcW Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammator…
Read more
health-issue
Press Release: Availability of the Q2 2024 Aide-mémoire
https://ift.tt/uiPfq5W Availability of the Q2 2024 Aide-mémoire from Sanofi - Aventis Groupe https://ift.tt/XoIW75n via IFTTT
Read more
health-issue
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
https://ift.tt/RHUqpgJ Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee from Sanofi - Aven…
Read more
health-issue
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
https://ift.tt/h5VgO4Q ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran from Sanofi - Aventis Groupe https…
Read more
health-issue
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
https://ift.tt/Fq7D06Y Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa from Sanofi - Aventis Groupe https://ift.tt/…
Read more